$-0.18 EPS Expected for Akcea Therapeutics Inc (AKCA)

November 7, 2017 - By Marie Mckinney

Wall Street await Akcea Therapeutics Inc (NASDAQ:AKCA) to release earnings on November, 14. After posting $-0.27 EPS for the previous quarter, Akcea Therapeutics Inc’s analysts now forecast -33.33 % EPS growth. The stock decreased 6.42% or $1.14 during the last trading session, reaching $16.61. About 338,101 shares traded. Akcea Therapeutics Inc (NASDAQ:AKCA) has 0.00% since November 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Akcea Therapeutics Inc (NASDAQ:AKCA) Ratings Coverage

Among 3 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc had 4 analyst reports since August 8, 2017 according to SRatingsIntel. Stifel Nicolaus maintained Akcea Therapeutics Inc (NASDAQ:AKCA) on Tuesday, October 31 with “Buy” rating. The company was initiated on Tuesday, August 8 by Stifel Nicolaus. BMO Capital Markets initiated Akcea Therapeutics Inc (NASDAQ:AKCA) on Tuesday, August 8 with “Buy” rating.

Akcea Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $1.11 billion. The Firm is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It currently has negative earnings. The Company’s drugs, volanesorsen, AKCEA-APO-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis).

More important recent Akcea Therapeutics Inc (NASDAQ:AKCA) news were published by: Globenewswire.com which released: “Akcea Therapeutics Named Among Top 100 Women-Led Businesses in Massachusetts …” on October 27, 2017, also Nasdaq.com published article titled: “Akcea Reports Financial Results and Highlights for Third Quarter 2017”, Globenewswire.com published: “Akcea Therapeutics to Hold Third Quarter 2017 Financial Results Webcast” on October 23, 2017. More interesting news about Akcea Therapeutics Inc (NASDAQ:AKCA) was released by: Globenewswire.com and their article: “Akcea Therapeutics’ Volanesorsen Receives Promising Innovative Medicine (PIM …” with publication date: October 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com